Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    -0.005 (-2.63%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Total Voting Rights

27 Feb 2009 07:00

RNS Number : 8822N
ValiRx PLC
27 February 2009
Β 

ο»Ώ

ValiRx plc

(the "Company")

Total Voting Rights

For the purposes of the transitional provisionsΒ of the Financial Services Authority's Disclosure and Transparency Rules, following the reorganisation of the Company's share capital announced on 13 February 2009, the total number of ordinary shares of 1p each in the capital of the Company in issue as at the date of this notice is 58,378,365 with each share carrying the right to one vote.

There are no shares held in treasury.

Therefore, the total number of voting rights in the Company remains unchanged at 58,378,365.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules.

For more information, please contact:

ValiRx plc

Dr. Satu Vainikka

Tel: +44 (0) 20 3008 4416

WH Ireland Limited

David Youngman/Adrian Kirk

Tel: +44 (0) 161 832 2174

College Hill

Adrian Duffield/Justine Lamond

Tel: +44 (0) 20 7457 2020

valirx@collegehill.com

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TVREASASALANEFE
Date   Source Headline
2nd Jun 20267:00 amRNSConclusion of Evaluation with Stingray
1st Jun 20267:00 amRNSValiRx Exercises Option on Evaluation Asset
27th May 20267:00 amRNSCytolytix Patent Granted
21st May 20267:00 amRNSResult of Oversubscribed WRAP Retail Offer
18th May 20267:00 amRNSWRAP Retail Offer for up to £150,000
15th May 20267:00 amRNSFundraising of up to £1,155,000
31st Mar 202610:15 amRNSChange of Registered Office
26th Mar 20267:00 amRNSValiRx Commercial Update Q1 2026
24th Mar 20267:00 amRNSValiRx and TwinEdge to present Digital Twin data
4th Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20267:00 amRNSValiRx forms ValiRx Animal Health Ltd subsidiary
19th Jan 20267:00 amRNSExercise of Warrants
9th Jan 20263:45 pmRNSReplacement: Evaluation and Transfer Agreement
9th Jan 20267:00 amRNSNew Evaluation and Material Transfer Agreement
8th Jan 20261:00 pmRNSHolding(s) in Company
5th Dec 202510:56 amRNSHolding(s) in Company
24th Nov 20253:54 pmRNSHolding(s) in Company
24th Nov 20259:30 amRNSHolding(s) in Company
20th Nov 202512:11 pmRNSResult of GM & Issue of Equity
13th Nov 20252:16 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSHolding(s) in Company
4th Nov 20255:15 pmRNSPosting of Circular and Notice of General Meeting
4th Nov 20257:00 amRNSResult of WRAP Retail Offer
30th Oct 20257:21 amRNSWRAP Retail Offer for up to £300,000
30th Oct 20257:17 amRNSFundraising of up to £1,050,000
14th Oct 20257:00 amRNSInaphaea Commercial update
29th Sep 20257:00 amRNSHalf-year Report
18th Sep 20257:00 amRNSInaphaea Commercial Update
1st Sep 20257:00 amRNSCytolytix Commercial update
26th Aug 20257:00 amRNSCommercial update
7th Aug 202510:51 amRNSValiRx Awarded Grant from Open University
5th Aug 20259:53 amRNSUpdate on Evaluation Agreement with Stingray Bio
4th Aug 20257:00 amRNSLicensing Agreement with Dominion Biotech Ltd
29th Jul 20257:00 amRNSCollaboration Agreement with Voxcell BioInnovation
30th Jun 20253:48 pmRNSResult of AGM
20th Jun 20257:00 amRNSAmbrose Exercise Option on VAL401
9th Jun 202510:57 amRNSValiRx Investor Webinar
6th Jun 202510:54 amRNSHolding(s) in Company
6th Jun 20257:00 amRNSFinal Results & Notice of AGM
3rd Jun 20257:00 amRNSNew Evaluation and Material Transfer Agreement
20th May 20251:25 pmRNSHolding(s) in Company
12th May 20257:00 amRNSInaphaea Deal Extension With Dominion
30th Apr 20257:00 amRNSCommercial Update
3rd Apr 20257:00 amRNSTermination of Letter of Intent with TheoremRx
27th Mar 20257:00 amRNSDirectorate Changes and new Advisory Board
21st Mar 202511:07 amRNSDirector Disclosure Update
24th Feb 20257:00 amRNSConclusion of Evaluation Project
3rd Feb 20257:00 amRNSInaphaea Evaluation and Commercial Use Agreement
30th Jan 20257:00 amRNSExtension of Evaluation Agreement
29th Jan 20257:00 amRNSNew Evaluation and Option Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.